<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847235</url>
  </required_header>
  <id_info>
    <org_study_id>OD_OA</org_study_id>
    <nct_id>NCT01847235</nct_id>
  </id_info>
  <brief_title>Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial</brief_title>
  <official_title>The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of temozolomide in patient
      with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic
      oligoastrocytoma will be enrolled. Enrolled patients will begin on temozolomide 200 mg/m2/d
      in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle). Patients who were
      previously treated with any chemotherapy initially received temozolomide 150 mg/m2/d for 5
      days (750 mg/m2 per cycle).Patients will be receving a total 6 cycles of chemotheray
      (4weeks/cycle * 6cycles = 24weeks). If the patients shows responses to Temozolomide,
      treatment can be continued by the investigator's discretion.

      During the administration of Temozolomide, vital signs, physical examination, ECOG
      performance status, height, weight, hematology and chemistry test, adverse events and
      concomitant drugs will be evaluated every four weeks. Brain MRI for tumor assessment will be
      performed once every 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 month</time_frame>
    <description>PFS will be examined with Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>ORR will be evaluated through the frequency analysis with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 years</time_frame>
    <description>OS will be examined with Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>PFS will be examined with Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>1 years</time_frame>
    <description>Regarding safety endpoints, all adverse events will be individually graded based on the CTCAE version 4.03. The number of participants with adverse events will be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Predictive biomarker study</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Anaplastic Oligoastrocytoma</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).</description>
    <arm_group_label>Temozolomide</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven anaplastic oligodendroglioma or oligoastrocytoma

          -  Progressed or relapsed after surgery or radiation therapy

          -  Female or male aged 20 years or over

          -  At least 1 measurable mass lesion

          -  ECOG performance status 0-3

          -  Adequate organ function

          -  absolute neutrophil count &gt; 1,500/μL

          -  platelet count &gt; 75,000/μL

          -  hemoglobin greater than 9 g/dL or 900g/L

          -  serum creatinine less than 1.5 times the upper limit of laboratory normal

          -  total serum bilirubin less than 1.5 times the upper limit of laboratory normal

          -  AST or ALT less than three times the upper limit of laboratory normal

        Exclusion Criteria:

          -  Prior course of temozolomide

          -  Combined glioblastoma

          -  Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae Min Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital, Seoul, South Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.</citation>
    <PMID>15758009</PMID>
  </reference>
  <reference>
    <citation>Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the &quot;rescue&quot; approach. Cancer. 2008 Oct 15;113(8):2152-7. doi: 10.1002/cncr.23813.</citation>
    <PMID>18756530</PMID>
  </reference>
  <reference>
    <citation>Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. doi: 10.1200/JCO.2009.26.5520. Epub 2010 Mar 22. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.</citation>
    <PMID>20308655</PMID>
  </reference>
  <reference>
    <citation>Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999 Sep;17(9):2762-71. Erratum in: J Clin Oncol 1999 Nov;17(11):3693.</citation>
    <PMID>10561351</PMID>
  </reference>
  <reference>
    <citation>Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9.</citation>
    <PMID>9776413</PMID>
  </reference>
  <reference>
    <citation>Van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol. 2008 Jun;66(3):262-72. doi: 10.1016/j.critrevonc.2007.11.007. Epub 2008 Feb 12. Review.</citation>
    <PMID>18272388</PMID>
  </reference>
  <reference>
    <citation>Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer. 2005 Jan 20;113(3):379-85.</citation>
    <PMID>15455350</PMID>
  </reference>
  <reference>
    <citation>Gan HK, Rosenthal MA, Dowling A, Kalnins R, Algar E, Wong N, Benson A, Woods AM, Cher L. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neuro Oncol. 2010 May;12(5):500-7. doi: 10.1093/neuonc/nop065. Epub 2010 Feb 8.</citation>
    <PMID>20406900</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <last_update_submitted>April 22, 2016</last_update_submitted>
  <last_update_submitted_qc>April 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Tae Min Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

